aTyr Pharma: Positive End-of-Phase 2 Meeting with FDA

  aTyr Pharma Inc.  (Nasdaq: LIFE) (aTyr or the “Company”), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the positive outcome of a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis. As a result, the Company intends to initiate a planned registrational study of efzofitimod in the third quarter of 2022.

https://www.biospace.com/article/releases/atyr-pharma-announces-positive-end-of-phase-2-meeting-with-fda-on-efzofitimod-for-the-treatment-of-pulmonary-sarcoidosis/